Evidence map›Paper›PMID 26106599›Full record

ReviewBioMed research international2015

Colorectal Cancer Biomarkers: Where Are We Now?

Maria Gonzalez-Pons, Marcia Cruz-Correa

Open access · hybridAbstract readReview
In one paragraph

Review in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 4 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 4 syntheses or guidelines pooled it, 211 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. A Systems Biology Approach Unveils a Critical Role of DPP4 in Upper Gastrointestinal Cancer Patient Outcomes.Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer · 2024
    Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. The Antioxidant and Antitumor Efficiency ofLife (Basel, Switzerland) · 2022
    Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Maria Gonzalez-PonsDepartment of Gastrointestinal Oncology and Genetics, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR 00927-6346, USA ; UPR-MDACC Partnership for Excellence in Cancer Research Program, University of Puerto Rico Medical Sciences Campus, San Juan, PR 00936-5067, USA.ORCID 0000-0002-3694-0534
Marcia Cruz-CorreaDepartment of Gastrointestinal Oncology and Genetics, University of Puerto Rico Comprehensive Cancer Center, San Juan, PR 00927-6346, USA ; UPR-MDACC Partnership for Excellence in Cancer Research Program, University of Puerto Rico Medical Sciences Campus, San Juan, PR 00936-5067, USA ; Department of Medicine, Biochemistry, and Surgery, University of Puerto Rico School of Medicine, San Juan, PR 00936-5067, USA.ORCID 0000-0001-8147-7457
University of Puerto Rico, Medical Sciences Campus · PR

Funding

UPR/MDACC Partnership for Excellence in Cancer Research(Parent Grant U54 CA096297)U54CA096297 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Ilka C Rios · 2002 to 2026
$36.9M
TECHNOLOGIES AND RESOURCES FOR CORE LABORATORIESU54MD007587 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI BENABE, JULIO E, LUCIANO, CARLOS A. · 2012 to 2018
$23.2M
TRCLU54RR026139 · NCRR · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI FRONTERA, WALTER R. · 2010 to 2011
$8.4M
Clinicopathology of IGF2 loss of imprinting in colon neoplasiaK22CA115913 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CRUZ-CORREA, MARCIA ROXANA · 2007 to 2009
$621k
Human Papilloma Virus Infection in Patients with Colorectal CancerR21CA167220 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CRUZ-CORREA, MARCIA ROXANA · 2012 to 2013
$404k
NCI NIH HHS 5K22CA115913-03NCI NIH HHS K22 CA115913NCI NIH HHS R21 CA167220NCI NIH HHS R21CA167220-01NCI NIH HHS U54 CA096297NCI NIH HHS U54CA096297NCRR NIH HHS U54 RR026139NIMHD NIH HHS 8U54MD 007587-03NIMHD NIH HHS U54 MD007587
6 · The paper itself

Abstract

Colorectal cancer is one of the major causes of cancer-related death in the Western world. Patient survival is highly dependent on the tumor stage at the time of diagnosis. Reduced sensitivity to chemotherapy is still a major obstacle in effective treatment of advanced disease. Due to the fact that colorectal cancer is mostly asymptomatic until it progresses to advanced stages, the implementation of screening programs aimed at early detection is essential to reduce incidence and mortality rates. Current screening and diagnostic methods range from semi-invasive procedures such as colonoscopy to noninvasive stool-based tests. The combination of the absence of symptoms, the semi-invasive nature of currently used methods, and the suboptimal accuracy of fecal blood tests results in colorectal cancer diagnosis at advanced stages in a significant number of individuals. Alterations in gene expression leading to colorectal carcinogenesis are reflected in dysregulated levels of nucleic acids and proteins, which can be used for the development of novel, minimally invasive molecular biomarkers. The purpose of this review is to discuss the commercially available colorectal cancer molecular diagnostic methods as well as to highlight some of the new candidate predictive and prognostic molecular markers for tumor, stool, and blood samples.

Indexed as

Pathology, MolecularBiomarkers, TumorColonoscopyColorectal NeoplasmsFecesHumansMicroRNAsBiomarkers, TumorMicroRNAs

Identifiers

PMID26106599
PMCPMC4461726
OpenAlexW1554656018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.